Report Title:
Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) - Pipeline Review, H1 2018 Published On: January 2018
Category: Life Sciences
Pages: 97
Report Overview: Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Pipeline Review, H1 2018 Summary Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Receptor tyrosineprotein kinase erbB3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosineprotein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin1 NRG1 and is activated by it. It also activated by CSPG5. Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 pipeline Target constitutes close to 22 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 4, 2, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications NonSmall Cell Lung Cancer, Breast Cancer, Gastric Cancer, Solid Tumor, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Breast Cancer, Esophageal Cancer, Lung Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Metastatic Colorectal Cancer, Pancreatic Cancer, Recurrent Head And
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Neck Cancer Squamous Cell Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Colorectal Tumor, Endometrial Cancer, Epithelial Tumor, Ewing Sarcoma, Head And Neck Cancer, Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Malignant Mesothelioma, Metastatic Hepatocellular Carcinoma HCC, Metastatic Pancreatic Cancer, Nasopharyngeal Cancer, Neuroendocrine Tumors, Oral Cavity Mouth Cancer, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Tumor, Peritoneal Tumor, Skin Cancer, SmallCell Lung Cancer, Squamous NonSmall Cell Lung Cancer and Thyroid Cancer. The latest report Receptor Tyrosine Protein Kinase ERBB 3 Pipeline Review, H1 2018, outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 The report reviews Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects The report assesses Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1
24marketreports | International +1 646 781 7170 | www.24marketreports.com
targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type The report summarizes all the dormant and discontinued pipeline projects The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 targeted therapeutics Reasons to buy Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents: Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Overview Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Products under Development by Companies Products under Development by Universities/Institutes Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Companies Involved in Therapeutics Development AstraZeneca Plc AVEO Pharmaceuticals Inc Celldex Therapeutics Inc Daiichi Sankyo Co Ltd Etubics Corp F. HoffmannLa Roche Ltd GlaxoSmithKline Plc Hanmi Pharmaceuticals Co Ltd Hummingbird Bioscience Pte Ltd ImmunoGen Inc MediaPharma SRL Merrimack Pharmaceuticals Inc Merus NV Novartis AG Shanghai Fosun Pharmaceutical Group Co Ltd Sorrento Therapeutics Inc Symphogen A/S Takis Srl XuanZhu Pharma Co Ltd Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Drug Profiles AV203 Drug Profile Product Description Mechanism Of Action R&D Progress BA0702 Drug Profile Product Description Mechanism Of Action R&D Progress CDX3379 Drug Profile Product Description Mechanism Of Action R&D Progress elgemtumab Drug Profile Product Description
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Mechanism Of Action R&D Progress ETBX031 Drug Profile Product Description Mechanism Of Action R&D Progress FCN411 Drug Profile Product Description Mechanism Of Action R&D Progress GSK2849330 Drug Profile Product Description Mechanism Of Action R&D Progress HMBD001 Drug Profile Product Description Mechanism Of Action R&D Progress huHER38 Drug Profile Product Description Mechanism Of Action R&D Progress istiratumab Drug Profile Product Description Mechanism Of Action R&D Progress KBP5209 Drug Profile Product Description Mechanism Of Action R&D Progress lumretuzumab Drug Profile Product Description Mechanism Of Action R&D Progress MCLA125 Drug Profile Product Description Mechanism Of Action R&D Progress MPEV201959 Drug Profile Product Description Mechanism Of Action R&D Progress patritumab Drug Profile Product Description Mechanism Of Action R&D Progress
24marketreports | International +1 646 781 7170 | www.24marketreports.com
poziotinib Drug Profile Product Description Mechanism Of Action R&D Progress sapitinib Drug Profile Product Description Mechanism Of Action R&D Progress seribantumab Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit EGFR, HER2 and HER3 for Oncology Drug Profile Product Description Mechanism Of Action R&D Progress Sym013 Drug Profile Product Description Mechanism Of Action R&D Progress TK003 Drug Profile Product Description Mechanism Of Action R&D Progress XZP5491 Drug Profile Product Description Mechanism Of Action R&D Progress Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Dormant Products Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Discontinued Products Receptor Tyrosine Protein Kinase ERBB 3 Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1 Product Development Milestones Featured News & Press Releases Dec 21, 2017: CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer ESCC In China Nov 17, 2017: Celldex Therapeutics Initiates Phase 2 Combination Study of CDX3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma Oct 30, 2017: Merrimack Receives Orphan Drug Designation for MM121 for the Treatment of Heregulin Positive Nonsmall Cell Lung Cancer Oct 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Multicenter Phase 2 Trial of Poziotinib in NonSmall Cell Lung Cancer NSCLC Patients with Exon 20 Insertion Mutation in EGFR or HER2
24marketreports | International +1 646 781 7170 | www.24marketreports.com
Oct 17, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in NonSmallCell Lung Cancer NSCLC Presented at the 18th IASLC World Conference on Lung Cancer in Japan Sep 28, 2017: Spectrum Pharmaceuticals Highlights Poziotinib Data in Lung Cancer to be Presented in an Oral Presentation at the 18th IASLC World Conference on Lung Cancer in Yokohama, Japan, October 1518, 2017 Sep 13, 2017: AVEO Oncology Announces Receipt of $0.5 million Payment from CANbridge Jun 19, 2017: Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM141; Data Expected in First Half of 2018 Apr 03, 2017: AVEO Announces Milestone Payment from CANbridge for AV203 Apr 03, 2017: Hummingbird Bioscience presents update on HMBD001 at AACR in Washington DC Mar 30, 2017: Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in NonSmall Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Mar 27, 2017: Merrimack to Present Data on Istiratumab MM141 at the 2017 American Association for Cancer Research Annual Meeting Dec 08, 2016: Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer Dec 05, 2016: Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium SABCS in San Antonio, Texas, December 610, 2016 Nov 17, 2016: Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna, Austria, December 47, 2016 Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
Get More Information about the Report: Report URL: https://www.24marketreports.com/life-sciences/receptor-tyrosine-protein-kinase-erbb-3-proto-o ncogene-like-protein-c-erbb-3-or-tyrosine-kinase-type-cell-surface-receptor-her3-or-her3-orerbb3-or-ec-27101pipeline-review-h1-2018-market-11 To get Report Sample: https://www.24marketreports.com/request-sample/receptor-tyrosine-protein-kinase-erbb-3-prot o-oncogene-like-protein-c-erbb-3-or-tyrosine-kinase-type-cell-surface-receptor-her3-or-her3-orerbb3-or-ec-27101pipeline-review-h1-2018-market-11
24marketreports | International +1 646 781 7170 | www.24marketreports.com